AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Summit Therapeutics Inc. Director's Dealing 2025

Jan 14, 2025

30436_dirs_2025-01-14_58aeec8c-798a-4411-ac5c-cb3d7f950518.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Summit Therapeutics Inc. (SMMT)
CIK: 0001599298
Period of Report: 2025-01-12

Reporting Person: Anand Bhaskar (Chief Accounting Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-01-12	Stock Option (right to buy)	$17.85	A	75000	Acquired	2035-01-12	Common Stock (75000)	Direct

Footnotes

F1: The option was granted on January 12, 2025. The shares underlying the option shall vest in four equal annual installments, with the first such installment occurring on January 12, 2026.

F2: Not Applicable.